{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T14:01:25Z","timestamp":1700056885339},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T00:00:00Z","timestamp":1185753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe patterns of sibutramine usage in New Zealand during the first 3 years of marketing using data acquired during post\u2010marketing safety surveillance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Demographic and prescription data were examined from a nationwide cohort of 17\u2009298 patients prescribed sibutramine between 1 February 2001 and 31 March 2004. Outcome measures were age and sex distribution of the cohort; period prevalence of sibutramine usage for each ethnic group; duration of treatment and reasons for cessation of therapy. Limited BMI data were also examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>About 0.5% of the NZ population were prescribed sibutramine in the period studied. Overwhelmingly, the highest users of sibutramine were NZ European women aged 30\u201359 years. Maori and Pacific Peoples were under\u2010represented in the cohort, despite the higher prevalence of obesity among these populations. Sibutramine usage was predominantly short\u2010term: 59% of the cohort used sibutramine for 90 days or less, half of whom used it for only 1 month.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There has been extensive use of sibutramine in New Zealand. Sibutramine has been relatively under\u2010utilised by Maori and Pacific ethnic groups, compared to New Zealand Europeans, despite their higher prevalence of obesity. A number of factors may have contributed to the predominantly short\u2010term use of this medicine, including the cost of the medicine to the consumer, weight loss not meeting expectations and adverse effects of the medicine. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1447","type":"journal-article","created":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T11:47:35Z","timestamp":1185796055000},"page":"1217-1226","source":"Crossref","is-referenced-by-count":5,"title":["Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme"],"prefix":"10.1002","volume":"16","author":[{"given":"Geraldine R.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Harrison\u2010Woolrych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,26]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.9.994"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.152"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta6060"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802475"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1395"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.4.942"},{"key":"e_1_2_1_8_2","unstructured":"BarbehennE LurieP WolfeS.Petition supplement to FDA outlining the rising number of cardiovascular events associated with the diet drug sibutramine (MERIDIA) (HRG Publication #1675)http:\/\/www.citizen.org\/publications\/release.cfm?ID=7273. Accessed 19 April 2006."},{"key":"e_1_2_1_9_2","unstructured":"WolfeSM SasichLD BarbehennE.Public Citizen Health Research Group.Petition to FDA to ban the diet drug sibutramine (MERIDIA) (HRG Publication #1613).http:\/\/www. citizen.org\/publications\/print_release.cfm?ID=7160. Accessed 1 September 2005."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326140-00004"},{"key":"e_1_2_1_11_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP).Committee for Proprietary Medicinal Products opinion following an article 31 referral. Sibutramine: european agency for the evaluation of medicinal products; 2 December2002CPMP\/4514\/02\/Final."},{"key":"e_1_2_1_12_2","unstructured":"Abbott Laboratories (NZ) Ltd.New Zealand data sheet for Reductil. May2006;http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/r\/Reductilcap.htm. Accessed 9 Jan 2007."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.13.1703"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/0470853093.ch27"},{"key":"e_1_2_1_15_2","unstructured":"New Zealand Health Information Service (NZHIS).Guide to NZHIS national collections: National Health Index (NHI). 22 Oct2003;http:\/\/www.nzhis.govt.nz\/collections\/collections\u2010nhi.html. Accessed 4 Dec 2006."},{"key":"e_1_2_1_16_2","unstructured":"Statistics New Zealand.Table 2b: ethnic group \u2010 up to three responses (Single and Combination) and sex for the census usually resident population count 1991 1996 and 2001http:\/\/www.stats.govt.nz. Accessed October2006."},{"key":"e_1_2_1_17_2","unstructured":"Ministry of Health.Tracking the obesity epidemic: New Zealand 1977\u20102003. Wellington: Ministry of Health; December2004. HP 4010."},{"key":"e_1_2_1_18_2","unstructured":"Ministry of Health.The New Zealand health strategy. Wellington: Ministry of Health;2000(Available on\u2010line athttp:\/\/www.moh.govt.nz)."},{"key":"e_1_2_1_19_2","unstructured":"Ministry of Health.Healthy eating\u2013healthy action: oranga kai\u2013oranga pumau. A strategic framework. Wellington: Ministry of Health; March2003. HP3606 (Available on\u2010line athttp:\/\/www.moh.govt.nz)."},{"key":"e_1_2_1_20_2","unstructured":"Ministry of Health.A portrait of health: key results of the 2002\/03 New Zealand health survey. Wellington: Ministry of Health; August2004(Available on\u2010line athttp:\/\/www.moh.govt.nz)."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0263"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.14.1805"},{"key":"e_1_2_1_23_2","unstructured":"SalmondC CramptonP.NZDep2001 index of deprivation user's manual.http:\/\/www.moh.govt.nz\/moh.nsf\/Files\/phi\u2010users\u2010manual\/$file\/phi\u2010users\u2010manual.pdf. Accessed 11 August 2005."},{"issue":"1173","key":"e_1_2_1_24_2","first-page":"U416","article-title":"New Zealand's primary health care strategy: what are the costs and how likely are the benefits?","volume":"116","author":"Raymont A","year":"2003","journal-title":"New Zealand Med J"},{"key":"e_1_2_1_25_2","unstructured":"Ministry of Health.Modelling diabetes: forecasts to 2011. Wellington: Ministry of Health; March2002. HP3491 (Available on\u2010line athttp:\/\/www.moh.govt.nz)."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta8210"},{"issue":"1","key":"e_1_2_1_27_2","article-title":"Pharmacotherapy for weight loss in adults with Type 2 diabetes mellitus [Systematic Review]","author":"Norris SL","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.71.6.1084"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802475"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802982"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1447","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:13:00Z","timestamp":1700010780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,26]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1002\/pds.1447"],"URL":"https:\/\/doi.org\/10.1002\/pds.1447","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,26]]}}}